[ad_1]
Exclusive development and commercialization rights to VIR-3434 in China strengthen Company’s leadership and robust clinical pipeline in HBV
Key partnership with Vir enables multitude of combination treatment options as part of the Company’s strategic approach to developing a functional cure for HBV
DURHAM, NC and BEIJING, July 3, 2022 /PRNewswire/ — Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that it exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. ((", Vir", , NASDAQ:VIR). This move provides additional growth to the Company’s leading clinical pipeline of therapeutic candidates for hepatitis B virus (HBV) and provides an expansive set of potential combination treatment options for Brii Bio to explore as part of its efforts to develop a functional cure for HBV.
Full story available on Benzinga.com
[ad_2]
Source link
